Clinical Trials Logo

Clinical Trial Summary

This study is being conducted to evaluate the safety, efficacy (clinical and microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it would be a suitable antibiotic for the treatment for febrile lower cUTI and pyelonephritis(complicated and uncomplicated). GSK2251052 will be compared to imipenem-cilastatin, which is an antibiotic commonly used to treat serious cUTI infections. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cUTI.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01381549
Study type Interventional
Source GlaxoSmithKline
Contact
Status Terminated
Phase Phase 2
Start date June 2011
Completion date March 2012

See also
  Status Clinical Trial Phase
Completed NCT02446496 - A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects Phase 4
Not yet recruiting NCT06149455 - Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy N/A